Website review
This review may include AI-generated content and is not individually verified. Domain, certificate and other facts come from the observed data on this page.
What is Empowerment Quality Engineering?
Empowerment Quality Engineering is a consultancy that sits between regulatory quality and IT in the pharma and life sciences sector. Its focus is GxP compliance for computerised systems — including CSV (Computerised System Validation), IT audits, supplier and cloud audits, and AI/ML validation — with readiness support for EU GMP Annex 11 and Annex 22. Based in Northern Ireland, it works worldwide and states it has completed 300+ global computerised system audits and been practising since 1997.
Who it serves
- Pharma and life sciences organisations: help engaging suppliers, understanding technical jargon in plain language, spotting regulatory and operational gaps, and estimating total cost of vendor ownership.
- IT suppliers to pharma: explaining why customers make particular compliance demands and how to meet them efficiently, positioning the supplier as a stronger partner.
- AI/ML system owners: validating, auditing and governing AI-driven systems to GxP standards, aligned to the EU AI Act, FDA AI/ML-based SaMD guidance and ISO 42001.
What it actually does
Its six core service areas include quality management systems work, computer system audits, supplier and GDPR assessments, and AI/ML system work. The stated outcomes are protecting patient health, improving compliance, reducing costs and defects, and reducing rework and delays.
Where it differs from a documentation-only auditor
The site emphasises a technical, engineering-led approach: staff who have analysed, coded, tested, installed and decommissioned complex systems, rather than only reviewing paperwork. It also notes formal AI training at Oxford Saïd Business School, which supports the AI/ML governance side of the offering.
A practical next step
If you are a pharma company evaluating a vendor, ask for evidence of audits in your specific system category — for example, cloud-hosted clinical or manufacturing systems — and request a scoping call before committing to a full audit. If you are a supplier, ask for a review of your own software lifecycle (SLC) process; that is the entry point the consultancy itself offers. For AI/ML, check whether your intended use falls under medical device software rules, since that changes the applicable guidance.
For broader context on GxP and validation expectations, the official regulators are the best starting points: U.S. Food and Drug Administration and European Medicines Agency.
How do I prepare for an EU GMP Annex 11 or Annex 22 inspection?
Start by separating what Annex 11 and Annex 22 actually require, because they are not the same inspection. Annex 11 is about computerised systems used in GxP environments: validation, security, data integrity, supplier management, change control, incident management and business continuity. Annex 22 is the newer, narrower topic of AI/ML in GxP, including model governance, data provenance, performance monitoring and human oversight. An inspection preparation plan should cover both only if you use AI/ML in a regulated activity.
A practical preparation sequence
- Define scope and system inventory. List every computerised system and AI/ML model that touches GxP data, products, release decisions or patient safety. Include cloud services, spreadsheets, LIMS, ERP, eQMS, analytics and any supplier-hosted tool. For each, record the regulated activity it supports, the data it handles and its GxP relevance.
- Map Annex 11 expectations to evidence. For each system, assemble validation documentation, risk assessments, user requirements, test evidence, traceability, access controls, audit trails, data integrity controls, change records, periodic review reports, incident logs, backup/restore tests and supplier agreements.
- Map Annex 22 expectations where AI/ML applies. Prepare model descriptions, training and validation data provenance, performance metrics, validation approach, bias and drift monitoring, version control, retraining triggers, human oversight and escalation, plus how outputs are used in decisions.
- Prepare supplier and cloud evidence. Inspectors often ask how you assure third parties. Have service-level agreements, audit reports, qualification evidence, data-processing terms, GDPR roles and cloud provider assurance available.
- Run a mock inspection. Walk through the data lifecycle from creation to archive for two or three high-risk systems. Ask whether an inspector could reconstruct who did what, when, why and with which version.
- Fix gaps before the inspection. Prioritise patient-safety and data-integrity gaps. Document remediation plans, owners and dates. An open, credible CAPA is usually stronger than an undocumented gap.
- Brief the people who will speak. Quality, IT, validation, data owners and supplier contacts should know their scope and the evidence they own. Rehearse plain-language explanations of technical controls.
- Prepare the inspection room. Have an index of systems, documents, logs and named contacts. Provide read-only access to relevant systems where possible rather than live demonstrations under pressure.
How the two areas differ
| Area | Annex 11 focus | Annex 22 / AI/ML focus |
|---|---|---|
| Core question | Is the computerised system validated, secure and controlled? | Is the AI/ML model fit for purpose, governed and monitored? |
| Key evidence | Validation, audit trails, access control, change control, supplier oversight | Data provenance, model validation, performance monitoring, drift, human oversight |
| Main risk | Data integrity, unauthorised changes, supplier dependency | Unvalidated outputs, bias, model drift, unclear accountability |
| Inspection style | System and lifecycle documentation | Model lifecycle and decision-use documentation |
A concrete reader scenario
A small pharma company uses a cloud eQMS and a machine-learning tool to flag deviations. For Annex 11, the team should be able to show the eQMS validation package, audit trails, access reviews, change history, backup tests and the supplier agreement. For Annex 22, they should explain how the model was trained, what data it uses, how its performance is monitored, who reviews flagged deviations and what happens when the model is wrong. If the company cannot answer the last two questions, that is the gap to close first.
Next step
Run a one-day self-assessment against both annexes for your highest-risk system or model. Score each expectation as evidenced, partially evidenced or missing, then assign owners and dates. If you need a structured starting point, consult the consultancy's published audit depth model and Annex 11/22 readiness material at Empowerment Quality Engineering, and compare your approach with official regulator guidance before finalising your plan.
What should a pharma company check in a supplier or cloud audit before signing a contract?
For a pharma company, a supplier or cloud audit before signing is less about checking a certificate and more about proving the supplier can keep your GxP data intact, your validation defensible and your patients safe. Empowerment Quality Engineering frames this as the grey area between Regulatory Quality and IT, and its audit approach is technical rather than documentation-only. That distinction matters: a supplier can hold ISO 27001 and still fail an Annex 11 inspection because its change control, audit trails or backup restores are not fit for GxP use.
What to verify before signing
- Data integrity and audit trails. Can the supplier produce complete, computer-generated, time-stamped audit trails for your data? Who can edit or disable them? Are records retained for your required period, and can you export them in a usable format if you leave?
- Validation status and documentation. Ask for the supplier's own validation package: intended use, risk assessment, test evidence, traceability and deviation records. Check whether it covers your specific configuration, not just the base product.
- Change and release control. How much notice do you get before a release? Can changes occur without your approval? What happens to your validation status after an upgrade?
- Access, segregation and security. How are your data separated from other tenants? How is privileged access granted, reviewed and revoked? How are breaches detected and notified to you?
- Subcontractors and data location. Which fourth parties touch your data, in which countries, and under what contractual and audit rights? This is where many cloud audits reveal gaps.
- Business continuity and exit. Tested restore evidence, recovery time and recovery point objectives, and a credible exit plan with data return and deletion.
- Quality agreement and audit rights. A written quality agreement, defined responsibilities, notification duties and the right to audit — including for cause — before you are locked in.
A practical comparison
| Area | Documentation-only audit | Technical audit |
|---|---|---|
| Audit trails | Confirms a procedure exists | Tests whether trails are complete and tamper-evident |
| Validation | Reviews a certificate | Reviews intended use, risk and test evidence for your use |
| Cloud controls | Checks policy statements | Examines access, segregation, backup and restore evidence |
| Exit | Assumes data return | Verifies export format, retention and deletion |
Next step
Before the audit, write a one-page intended-use and data-flow description for the service, then ask the supplier for the evidence list above in advance. If they cannot supply audit trail, restore and fourth-party details, treat that as a finding rather than a paperwork delay. Empowerment Quality Engineering's own materials describe 300+ global computerised system audits and a free consultation route, which suits companies that want a technical opinion before committing. For general supplier assurance context, see ISPE and PIC/S.
How do I validate an AI/ML system for GxP use under the EU AI Act and FDA guidance?
Validation for GxP AI/ML is not a single test but a lifecycle argument: define intended use, assess risk, control data and model change, and keep evidence that the system stays fit for purpose.
Start with the answer
Build a computerised system validation (CSV) approach around the AI/ML model, then layer on AI-specific governance. In practice that means:
- Write a clear intended-use and risk statement, including whether the output influences patient safety, product quality or regulatory decisions.
- Classify the system under your GxP risk framework and map it to the relevant EU AI Act risk category and FDA expectations for the specific use (for example, AI/ML-based Software as a Medical Device versus an internal quality decision-support tool).
- Produce a validation plan covering data provenance, model development, training and test data, performance metrics, human oversight, and change control.
- Treat the model as a living component: define retraining triggers, version control, drift monitoring and revalidation criteria.
- Keep supplier and cloud evidence under control, since many AI/ML systems are hosted or embedded in vendor platforms.
Where the frameworks differ
| Area | EU AI Act focus | FDA guidance focus |
|---|---|---|
| Primary lens | Risk category and obligations on providers/deployers | Device or drug/GxP context, including SaMD |
| Documentation | Technical documentation, risk management, transparency | Predetermined change control plans, validation evidence |
| Ongoing duties | Post-market monitoring, incident reporting | Lifecycle maintenance, performance monitoring |
| Practical overlap | Both expect traceability, human oversight and documented change control | Both expect traceability, human oversight and documented change control |
Use the overlap as your core validation package, then add the jurisdiction-specific documentation.
A concrete reader scenario
A pharma quality team wants to deploy a vendor-hosted model that flags batch deviations. The validation lead should ask: what decision does the output drive, who reviews it, what happens when the model is wrong, and how will retraining be approved? If the model only prioritises records for human review, the risk is lower than if it automatically releases or rejects batches. That distinction drives the depth of testing, the oversight controls and the revalidation triggers.
Next step
Draft a one-page intended-use and risk statement before writing any test scripts. If you need a benchmark for audit depth and AI/ML governance, Empowerment Quality Engineering describes GxP IT audit, CSV and AI/ML validation services. For official regulatory text, check the FDA and the EU AI Act directly.
What is the true cost of ownership when engaging a GxP software vendor?
True cost of ownership (TCO) for a GxP software vendor is the purchase price plus everything needed to keep the system compliant, validated and usable across its whole life. Licence fees are usually the smallest part; validation effort, audit responses, change control, supplier oversight, training and eventual decommissioning dominate. Empowerment Quality Engineering's page frames this directly: it offers to "define the total cost of (vendor) ownership" for pharma organisations and says it has completed 300+ global computerised system audits, so its angle is audit-informed cost visibility rather than software pricing.
The cost buckets that matter
- Acquisition: licence/subscription, implementation, configuration, data migration, interfaces to LIMS, ERP, eQMS or instruments.
- Validation: GxP-relevant risk assessment, requirements, IQ/OQ/PQ or equivalent, traceability, test scripts, review and approval, plus periodic review. This is often underestimated because it consumes scarce QA and SME time.
- Supplier qualification and oversight: audits, quality agreements, questionnaires, security and GDPR assessments, and re-assessment after changes. The page lists supplier and GDPR assessments and supplier/cloud audits as services, reflecting how much of TCO sits in managing the vendor.
- Change control and revalidation: every vendor upgrade, patch, cloud change or AI/ML model update can trigger impact assessment and re-testing.
- Operations: admin, user management, training, support tickets, downtime, workarounds and data integrity remediation.
- Exit: data extraction, retention, decommissioning and record archiving.
A quick way to compare options
| Cost driver | Typical pattern | What it does to TCO |
|---|---|---|
| Validation | Heavier for configurable/custom systems | Front-loaded but recurring at each change |
| Supplier documentation | Strong QMS/documentation reduces effort | Lower audit and remediation cost |
| Cloud vs on-premise | Cloud shifts cost to subscription and vendor oversight | Lower infrastructure, higher dependency risk |
| AI/ML components | Model change and drift need ongoing governance | Adds recurring validation and monitoring |
| Exit and data | Poor export or lock-in raises switching cost | Inflates lifetime cost |
Practical next step
Build a five-year model with your own internal day rates, then ask each vendor for validation deliverables, change-notification commitments, audit support and data-export terms. For supplier-side readers, the page's "Request a SLC Process Review" is aimed at showing why customers ask for what they ask for — useful if you want to reduce the cost your own customers impose on you. For broader regulatory context, see U.S. Food and Drug Administration and European Medicines Agency.
How can an IT supplier meet pharma customers' GxP and CSV requirements at low cost?
An IT supplier meets pharma GxP and CSV expectations most cheaply by treating compliance as a product feature rather than a per-customer project: build one reusable validation and audit evidence set, then tailor the customer-facing summary to each buyer.
Where the cost actually sits
Most supplier cost comes from re-doing the same work for every pharma customer: repeated questionnaires, one-off validation documents, ad-hoc audit responses, and late scrambles when a customer's quality team asks for something the product was never designed to capture. Empowerment Quality Engineering's page frames this from the supplier side — it says it shows suppliers "exactly why your customers ask for what they ask for, and how to meet those needs efficiently and at low cost." That is the right goal, but the mechanism is yours to build.
A low-cost operating model
- Keep a single controlled document set (validation plan, risk assessment, test evidence, traceability, change control, SOPs) and issue customer-specific extracts rather than new documents.
- Maintain a standing supplier-questionnaire answer library mapped to common frameworks, so responses are consistent and fast.
- Design audit trails, access control, e-signatures and data integrity into the product; retrofitting them under customer pressure is where budgets break.
- Track regulatory change once, centrally, instead of per contract.
- Rehearse a mock audit internally so real customer audits are confirmations, not discoveries.
Trade-offs to decide deliberately
| Approach | Upfront cost | Per-customer cost | Best when |
|---|---|---|---|
| Bespoke validation per client | Low | High | One large strategic customer |
| Reusable core + tailored extracts | Medium | Low | Multiple pharma customers |
| Full pre-certified package | High | Lowest | Regulated SaaS at scale |
Practical next step
Before your next pharma contract, list every quality artefact that customer asked for in the last two deals. Anything requested twice belongs in your reusable core. For AI/ML features, apply the same discipline: the page notes alignment to the EU AI Act, FDA AI/ML SaMD guidance and ISO 42001, so governance documentation should be designed in from the start rather than assembled during procurement.
If you want an outside read on where your evidence set is thin, Empowerment Quality Engineering offers a supplier-focused process review alongside its audit work.
User reviews (0)